Adeno-Associated Virus Delivery Limitations for Neurological Indications
Abstract
In this commentary we discuss pitfalls and limitations of current adeno-associated virus (AAV) delivery routes, dose scaling, and the extrapolation of animal data to first-in-human (FIH) AAV clinical trials.Source
Benatti HR, Gray-Edwards HL. Adeno-Associated Virus Delivery Limitations for Neurological Indications. Hum Gene Ther. 2022 Jan;33(1-2):1-7. doi: 10.1089/hum.2022.29196.hrb. PMID: 35049369.DOI
10.1089/hum.2022.29196.hrbPermanent Link to this Item
http://hdl.handle.net/20.500.14038/51576PubMed ID
35049369ae974a485f413a2113503eed53cd6c53
10.1089/hum.2022.29196.hrb